Canadian paper backpedals from Gardasil side effects story

Carly Helfand Merck has already had its fair share of struggles with uptake rates for its HPV vaccine, Gardasil. A Toronto Star story from earlier this month, which focused on young ...

J&J awaits jury verdict over Risperdal patient’s breast development

Tracy Staton Did Johnson & Johnson hide Risperdal's potential to trigger breast growth in boys? Or did the drugmaker adequately disclose the potential side effect? A Philadelphia ...

Lilly’s new insulin is likely DOA after latest delay, analyst says

Damian Garde Eli Lilly's already-delayed new insulin has run into another roadblock, as potentially harmful liver side effects have sent the company back to the clinic, putting ...

Merck bets big on NGM with a $450M handshake

Damian Garde Taking a page from famed partners like Sanofi and Regeneron and Roche and Genentech, Merck has signed a sweeping R&D deal with biotech NGM Biopharmaceuticals, promising ...

FDA grants Celgene’s Revlimid new use as it moves toward $10B in sales

Eric Palmer Celgene's powerhouse cancer drug Revlimid generated nearly $ 5 billion for the company last year and has now gotten yet another FDA nod which analysts believe will ...

Sun billionaire Shanghvi becomes India’s richest person

Eric Palmer India's pharmaceutical industry has minted plenty of billionaires, and Sun Pharmaceutical founder Dilip Shanghvi is among those. But with his company set to take over ...

Novo Nordisk’s game-changing oral diabetes drug clears Phase II

Damian Garde Novo Nordisk's new oral diabetes drug measured up to its injected counterpart in a midstage study, promising results the company heralds as a milestone in the field. FierceBiotech ...

Bayer feels sting of mixed decision from NICE for Eylea’s use in diabetics

Emily Wasserman Bayer has won an approval from England's National Institute for Health and Care Excellence (NICE) for its popular eye drug Eylea. But it was a mixed result. The ...

Ariad activists rabble for Berger’s job and mount a proxy fight

Damian Garde Activist investor Alex Denner has made the rumors official: He wants Ariad Pharmaceuticals CEO Harvey Berger out, and he's willing to mount a proxy fight to get his ...

Ex-Merck analyst cops to insider trading in Idenix, Ardea buyouts

Damian Garde The former Merck employee charged with profiting off of M&A secrets has pleaded guilty to biotech's latest insider trading scandal. FierceBiotech News

Ariad activists strike up proxy fight to replace CEO Berger

Carly Helfand Let the proxy fight begin. Activist hedge fund and major Ariad Pharmaceuticals shareholder Sarissa Capital has its own ideas for who it wants in the company's CEO ...

Cerecor picks up a Lilly antidepressant with ambitions in addiction

Damian Garde Cerecor acquired the rights to an Eli Lilly antidepressant, planning to take the drug into Phase II as a treatment for addictive disorders.  FierceBiotech News
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS